Aortic spontaneous echocardiographic contrast and hemostatic markers in patients with nonrheumatic atrial fibrillation

Chest. 2002 Feb;121(2):500-5. doi: 10.1378/chest.121.2.500.

Abstract

Objectives: To determine the relationship between spontaneous echocardiographic contrast (SEC) in the descending thoracic aorta and plasma levels of hemostatic markers in patients with nonrheumatic atrial fibrillation (AF).

Design and settings: A cross-sectional study at a university hospital.

Patients and measurements: In 91 consecutive patients (mean +/- SE age, 70 +/- 1 years; 68 men) with nonrheumatic AF who underwent transesophageal echocardiography, plasma levels of markers for platelet activity (platelet factor 4 [PF4] and beta-thromboglobulin [beta-TG]), thrombotic status (thrombin-antithrombin III complex [TAT]), and fibrinolytic status (D-dimer and plasmin-alpha(2)-plasmin inhibitor complex [PIC]) were determined.

Results: Forty-three patients who had aortic SEC (AoSEC) were older (72 years vs 68 years; p < 0.05) and had a higher prevalence of chronic AF (88% vs 52%; p < 0.05) than 48 patients without AoSEC. TAT, PIC, and D-dimer levels were significantly higher in patients with AoSEC than in those without AoSEC, whereas PF4 and beta-TG levels were not different between the two groups. Although the prevalence of cerebral embolism did not differ between the two groups (23% vs 29%), the prevalence of peripheral embolism was higher in patients with AoSEC than in those without AoSEC (10% vs 0%; p < 0.05). Multivariate analysis revealed mitral regurgitation (odds ratio, 7.53; p < 0.02), SEC in the left atrium (odds ratio, 2.14; p < 0.02), and aortic atherosclerosis (odds ratio, 1.87; p < 0.04) emerged as independent predictors of AoSEC.

Conclusions: Patients with nonrheumatic AF who have AoSEC appear to have enhanced coagulation activity but not platelet activity. Intensive anticoagulation treatment might be required for these patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antithrombin III / analysis
  • Aorta, Thoracic / diagnostic imaging*
  • Aortic Diseases / diagnostic imaging
  • Arteriosclerosis / diagnostic imaging
  • Atrial Fibrillation / blood*
  • Atrial Fibrillation / diagnostic imaging*
  • Cross-Sectional Studies
  • Echocardiography, Transesophageal
  • Female
  • Fibrin Fibrinogen Degradation Products / analysis
  • Fibrinolysis
  • Hemostasis*
  • Humans
  • Intracranial Embolism / diagnosis
  • Magnetic Resonance Imaging
  • Male
  • Peptide Hydrolases / analysis
  • Platelet Factor 4 / analysis
  • Tomography, X-Ray Computed
  • beta-Thromboglobulin / analysis

Substances

  • Fibrin Fibrinogen Degradation Products
  • antithrombin III-protease complex
  • beta-Thromboglobulin
  • fibrin fragment D
  • Platelet Factor 4
  • Antithrombin III
  • Peptide Hydrolases